Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIRADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIRADON.
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs MIRADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa). This prevents fibrin formation and clot propagation. It also inhibits factors IXa, XIa, and XIIa.
MIRADON (anagrelide) inhibits cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipids, possibly by inhibiting phospholipase A2. It also suppresses megakaryocyte maturation and platelet production.
Continuous IV infusion: Initial bolus of 5,000 units, then 1,000 units/hour (25,000 units/24h) adjusted based on aPTT. Typical infusion rate 10-20 units/kg/hour.
2.5 mg orally twice daily (total daily dose 5 mg)
None Documented
None Documented
30–150 minutes (intravenous), dose-dependent; at therapeutic doses ~60 minutes; prolonged in hepatic disease.
Terminal elimination half-life is 8-12 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 20-30 hours. The half-life supports twice-daily dosing in most patients.
Renal: negligible; biliary/fecal: negligible; primarily cleared by hepatic depolymerization and reticuloendothelial system uptake.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose. Fecal/biliary excretion accounts for 20-25%, with the remainder as oxidative metabolites. Up to 10% is eliminated as glucuronide conjugates.
Category A/B
Category C
Anticoagulant
Anticoagulant